Literature DB >> 16525157

Rho kinase regulates renal blood flow by modulating eNOS activity in ischemia-reperfusion of the rat kidney.

Amanda M G Versteilen1, Iolente J M Korstjens, René J P Musters, A B Johan Groeneveld, Pieter Sipkema.   

Abstract

Renal ischemia-reperfusion (I/R) results in vascular dysfunction characterized by a reduced endothelium-dependent vasodilatation and subsequently impaired blood flow. In this study, we investigated the role of Rho kinase in endothelial nitric oxide synthase (eNOS)-mediated regulation of renal blood flow and vasomotor tone in renal I/R. Male Wistar rats were subjected to 60-min bilateral clamping of the renal arteries or sham procedure. One hour before the clamping, the Rho kinase inhibitor Y27632 (1 mg/kg) was intravenously infused. After I/R, renal blood flow was measured using fluorescent microspheres. I/R resulted in a 62% decrease in renal blood flow. In contrast, the blood flow decrease in the group treated with the Rho kinase inhibitor (YI/R) was prevented. Endothelium-dependent vasodilatation of renal arcuate arteries to ACh was measured ex vivo in a pressure myograph. These experiments demonstrated that the in vivo treatment with the Rho kinase inhibitor prevented the decrease in the nitric oxide (NO)-mediated vasodilator response. In addition, after I/R renal interlobar arteries showed a decrease in phosphorylated eNOS and vasodilator-stimulated phosphoprotein, a marker for bioactive NO, which was attenuated by in vivo Rho kinase inhibition. These findings indicate that in vivo inhibition of Rho kinase in renal I/R preserves renal blood flow by improving eNOS function.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16525157     DOI: 10.1152/ajprenal.00434.2005

Source DB:  PubMed          Journal:  Am J Physiol Renal Physiol        ISSN: 1522-1466


  17 in total

1.  Renal hypoperfusion and impaired endothelium-dependent vasodilation in an animal model of VILI: the role of the peroxynitrite-PARP pathway.

Authors:  Rosanna Vaschetto; Jan W Kuiper; René J P Musters; Etto C Eringa; Francesco Della Corte; Kanneganti Murthy; A B Johan Groeneveld; Frans B Plötz
Journal:  Crit Care       Date:  2010-03-26       Impact factor: 9.097

2.  Effects of ischemic preconditioning on the systemic and renal hemodynamic changes in renal ischemia reperfusion injury.

Authors:  Yu-Zheng Ge; Ran Wu; Hui Xin; Hao Liu; Tian-Ze Lu; You-Cai Zhao; Jiang-Wei Shen; Zhi-Kai Hu; Peng Yu; Liu-Hua Zhou; Lu-Wei Xu; Zheng Xu; Jian-Ping Wu; Wen-Cheng Li; Jia-Geng Zhu; Rui-Peng Jia
Journal:  Int J Clin Exp Pathol       Date:  2015-02-01

3.  Rho-kinase signalling regulates CXC chemokine formation and leukocyte recruitment in colonic ischemia-reperfusion.

Authors:  Stefan Santen; Yusheng Wang; Matthias W Laschke; Michael D Menger; Bengt Jeppsson; Henrik Thorlacius
Journal:  Int J Colorectal Dis       Date:  2010-07-01       Impact factor: 2.571

4.  Gender differences affect blood flow recovery in a mouse model of hindlimb ischemia.

Authors:  Xinzhi Peng; Jinsong Wang; Roberta M Lassance-Soares; Amir H Najafi; Subeena Sood; Nima Aghili; Lee O Alderman; Julio A Panza; James E Faber; Shenming Wang; Stephen E Epstein; Mary Susan Burnett
Journal:  Am J Physiol Heart Circ Physiol       Date:  2011-03-11       Impact factor: 4.733

5.  AMPK activator AICAR ameliorates ischaemia reperfusion injury in the rat kidney.

Authors:  J Lempiäinen; P Finckenberg; J Levijoki; E Mervaala
Journal:  Br J Pharmacol       Date:  2012-07       Impact factor: 8.739

Review 6.  Renal endothelial dysfunction in acute kidney ischemia reperfusion injury.

Authors:  David P Basile; Mervin C Yoder
Journal:  Cardiovasc Hematol Disord Drug Targets       Date:  2014

Review 7.  Novel pharmacological approaches to the treatment of renal ischemia-reperfusion injury: a comprehensive review.

Authors:  Prabal K Chatterjee
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-09-22       Impact factor: 3.000

Review 8.  P2 receptors in renal autoregulation.

Authors:  Zhengrong Guan; Robert C Fellner; Justin Van Beusecum; Edward W Inscho
Journal:  Curr Vasc Pharmacol       Date:  2014       Impact factor: 2.719

9.  Interleukin-17 causes Rho-kinase-mediated endothelial dysfunction and hypertension.

Authors:  Hoanglan Nguyen; Valorie L Chiasson; Piyali Chatterjee; Shelley E Kopriva; Kristina J Young; Brett M Mitchell
Journal:  Cardiovasc Res       Date:  2012-12-21       Impact factor: 10.787

10.  Inhibition of renal rho kinase attenuates ischemia/reperfusion-induced injury.

Authors:  Jai Prakash; Martin H de Borst; Marie Lacombe; Frank Opdam; Pieter A Klok; Harry van Goor; Dirk K F Meijer; Frits Moolenaar; Klaas Poelstra; Robbert J Kok
Journal:  J Am Soc Nephrol       Date:  2008-07-23       Impact factor: 10.121

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.